Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
Matsubara N, de Bono J, Olmos D, Procopio G, Kawakami S, Ürün Y, van Alphen R, Flechon A, Carducci MA, Choi YD, Hotte SJ, Korbenfeld E, Kramer G, Agarwal N, Chi KN, Dearden S, Gresty C, Kang J, Poehlein C, Harrington EA, Hussain M. Matsubara N, et al. Among authors: carducci ma. Clin Cancer Res. 2023 Jan 4;29(1):92-99. doi: 10.1158/1078-0432.CCR-21-3577. Clin Cancer Res. 2023. PMID: 36318705 Free PMC article. Clinical Trial.
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Halabi S, Roy A, Rydzewska L, Guo S, Godolphin P, Hussain M, Tangen C, Thompson I, Xie W, Carducci MA, Smith MR, Morris MJ, Gravis G, Dearnaley DP, Verhagen P, Goto T, James N, Buyse ME, Tierney JF, Sweeney C; STOPCAP/ICECaP Collaboration. Halabi S, et al. Among authors: carducci ma. J Clin Oncol. 2024 Mar 20;42(9):1044-1054. doi: 10.1200/JCO.23.01535. Epub 2024 Jan 5. J Clin Oncol. 2024. PMID: 38181323
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Appleman LJ, et al. Among authors: carducci ma. J Clin Oncol. 2024 Mar 26:JCO2301544. doi: 10.1200/JCO.23.01544. Online ahead of print. J Clin Oncol. 2024. PMID: 38531002
Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study.
Eggly S, Senft N, Kim S, Heath EI, Jang H, Moore TF, Baidoun F, Manning MA, Penner LA, Albrecht TL, Carducci MA, Lansey D, Hamel LM. Eggly S, et al. Among authors: carducci ma. Cancer Med. 2023 Apr;12(7):8604-8613. doi: 10.1002/cam4.5552. Epub 2022 Dec 20. Cancer Med. 2023. PMID: 36540051 Free PMC article. Clinical Trial.
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
Jasmine S, Mandl A, Krueger TEG, Dalrymple SL, Antony L, Dias J, Celatka CA, Tapper AE, Kleppe M, Kanayama M, Jing Y, Speranzini V, Wang YZ, Luo J, Trock BJ, Denmeade SR, Carducci MA, Mattevi A, Rienhoff HY Jr, Isaacs JT, Nathaniel Brennen W. Jasmine S, et al. Among authors: carducci ma. Prostate. 2024 Apr 15. doi: 10.1002/pros.24707. Online ahead of print. Prostate. 2024. PMID: 38619005
Role of bromodomain and extraterminal (BET) proteins in prostate cancer.
Mandl A, Markowski MC, Carducci MA, Antonarakis ES. Mandl A, et al. Among authors: carducci ma. Expert Opin Investig Drugs. 2023 Mar;32(3):213-228. doi: 10.1080/13543784.2023.2186851. Epub 2023 Mar 9. Expert Opin Investig Drugs. 2023. PMID: 36857796 Review.
342 results